Back to search results

Study on Gallotannins, Gut Microbiome, and Inflammation in Obesity

This study is looking at how special mangoes, rich in gallotannins (a type of plant compound), and a probiotic called Lactiplantibacillus pentosus might affect the gut microbiome (the community of bacteria in your gut) and inflammation in people with obesity. Researchers want to see how these interventions change the gut bacteria and the byproducts they make, called short-chain fatty acids (SCFAs). They also want to understand how gallotannins are processed in the gut. The study will include 20 adults, aged 18 to 55, who are either lean or have obesity. The goal is to find out if these interventions can help reduce inflammation linked to obesity.

Study design
This interventional study plans to enroll 20 participants. It will compare the effects of gallotannin-rich mango, Lactiplantibacillus pentosus, and a group with no added treatment.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary outcomes will be measured at baseline and at the end of treatment at 12 hours (in vitro assessment).

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07505212

Effects of Gallotannins on the Gut Microbiome and How it Affects Inflammatory Markers Among Obese Individuals.

Active, Not Recruiting
NAAges 18–55InterventionalTreatment
Prairie View A&M University
~20 participants
Updated 2026-06-09 on ClinicalTrials.gov
What's tested:Gallotannin-rich mangoLactiplantibacillus pentosus (probiotic)No Treatment Added

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Levels of GT metabolites and short-chain fatty acids (SFCAs) and changes in gut microbiome using HPLC-ESI-MSⁿ and 16s rDNA sequencing, respectively.
Measured over Baseline (for all outcome measures) End of treatment at 12 hours (in vitro assessment)

Conditions

Obesity (Disorder)

Explore related trials

Obesity

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • Janet Antwi, Doctor of Philosophy · PRINCIPAL_INVESTIGATOR · Prairie View A&M University

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

Participants with history of acute cardiac events, stroke, or cancer, recurrent hospitalizations, drug treatment of listed conditions within 6 months before study begin, abuse of alcohol/substance, on medications against T2DM or related diseases, smoking \> 1 pack/week, seizures (all within the last 6 months) will be excluded from the study.
Participants with history of liver, intestinal or renal dysfunction, pregnancy or lactation, allergy against GTs, mangos, history of hepatitis B, C, or HIV, use of systemic antibiotics within 1 months of screening, participation in other interventional research study, intake of herbal dietary supplements.

What this trial measures

  • Levels of GT metabolites and short-chain fatty acids (SFCAs) and changes in gut microbiome using HPLC-ESI-MSⁿ and 16s rDNA sequencing, respectively.Baseline (for all outcome measures) End of treatment at 12 hours (in vitro assessment)

    GT metabolites and short-chain fatty acids (SCFAs) will be quantified using HPLC-ESI-MSⁿ, an advanced analytical technique that integrates compound separation, ionization, and structural characterization. In this method, HPLC separates mixture components based on their chemical properties, after which electrospray ionization (ESI) converts analytes into charged ions while preserving their structure. These ions are then subjected to multi-stage mass spectrometry (MSⁿ), enabling successive fragmentation and detailed structural identification of metabolites. Changes in gut microbiome composition will be assessed using 16S rDNA sequencing, a molecular technique that identifies and characterizes bacteria based on the highly conserved 16S ribosomal RNA gene. This involves DNA extraction, PCR amplification of the 16S rRNA gene, sequencing of variable regions, and comparison with reference databases to determine microbial diversity and composition.